{"id":35926,"date":"2026-09-25T09:57:03","date_gmt":"2026-09-25T13:57:03","guid":{"rendered":"https:\/\/joinastudy.ca\/?p=35926"},"modified":"2026-09-25T11:49:16","modified_gmt":"2026-09-25T15:49:16","slug":"glp-1-microdosing-for-longevity-whats-actually-been-studied","status":"publish","type":"post","link":"https:\/\/joinastudy.ca\/fr\/glp-1-microdosing-for-longevity-whats-actually-been-studied\/","title":{"rendered":"GLP-1 Microdosing for Longevity: What’s Actually Been Studied"},"content":{"rendered":"

This article is an addendum to our previously published series on GLP-1s. If you are interested in catching up on our previous articles on this subject, you can click here to be directed to the series intro<\/strong><\/a>.\u00a0<\/em><\/p>\n

Scroll through longevity TikTok or a biohacker newsletter right now and you’ll run into a confident claim: take a tiny weekly dose of semaglutide (way below the amount used for weight loss) and you’ll quiet inflammation, protect your mitochondria, and maybe even slow aging itself. No nausea, no dramatic weight loss, just the \u00ab\u00a0anti-aging\u00a0\u00bb benefits of GLP-1 drugs without the downsides.<\/p>\n

It’s a seductive pitch. It’s also, right now, almost entirely unproven.<\/p>\n

Here’s what’s actually been studied, what’s just theory borrowed from a bigger drug class, and what you should know before anyone hands you a vial.<\/p>\n

The claim<\/h3>\n

\u00ab\u00a0Microdosing\u00a0\u00bb GLP-1 medications means taking roughly 0.1\u20130.5 mg of semaglutide weekly. This is a fraction of the 2.4 mg maximum dose approved for weight loss. The pitch, mostly coming from longevity clinics and telehealth compounding pharmacies, is that at these low doses you get GLP-1’s supposed anti-inflammatory and metabolic benefits without appetite suppression, muscle loss, or GI side effects. In this usage case it becomes a general-purpose \u00ab\u00a0health span\u00a0\u00bb drug for people who aren’t overweight at all.<\/p>\n

The term itself is borrowed wholesale from psychedelics research, where \u00ab\u00a0microdose\u00a0\u00bb describes an amount deliberately below the threshold of pharmacological activity. Whether that concept translates meaningfully to a peptide drug that stays active in your body for roughly a week is a separate question \u2014 one no one has been able to answer yet.<\/p>\n

What’s actually true: the mechanism isn’t fiction<\/h3>\n

To be fair to the hype, this isn’t built on nothing. GLP-1 receptors exist well beyond the gut (they are found in the brain, heart, kidneys, and immune cells), and full-dose GLP-1 drugs have shown real, trial-confirmed effects outside of weight loss: reduced cardiovascular events, improvements in kidney disease markers, and emerging signals in heart failure and peripheral artery disease. Researchers investigating microdosing for longevity are hypothesizing that GLP-1 receptor activation at low levels could reduce inflammation, support mitochondrial function, and offer some neuroprotective effect; all which are plausible extensions of mechanisms seen at therapeutic doses.<\/p>\n

Plausible is the operative word. Almost none of that has been tested at microdose levels in controlled trials.<\/p>\n

What hasn’t been shown<\/h3>\n

This is the part that gets lost between the headline and the compounding pharmacy checkout page:<\/p>\n